Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Tonix Pharma ( (TNXP) ) has issued an announcement.
On February 6, 2025, Tonix Pharmaceuticals announced encouraging Phase 1 trial results for its TNX-1500 product, a next-generation anti-CD40L monoclonal antibody, in healthy participants. The trial demonstrated that TNX-1500 was well-tolerated and effective in modulating immune responses, showing potential as a superior option in preventing organ transplant rejection with reduced toxicity compared to existing immunosuppressive treatments.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates within the pharmaceutical industry, focusing on innovative therapies. Its primary product offerings include monoclonal antibodies, with current developments aimed at improving transplant outcomes.
YTD Price Performance: -54.58%
Average Trading Volume: 1,405,056
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $83.74M
For detailed information about TNXP stock, go to TipRanks’ Stock Analysis page.
